Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JB3H
|
|||
| Drug Name |
Omaveloxolone
|
|||
| Synonyms |
RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Friedreich's ataxia [ICD-11: 8A03.10; ICD-9: 334] | Approved | [1] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1/2 | [2] | ||
| Psychiatric disorder [ICD-11: 6E8Z] | Clinical trial | [3] | ||
| Company |
Reata Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H44F2N2O3
|
|||
| Canonical SMILES |
CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)NC(=O)C(C)(F)F)C
|
|||
| InChI |
1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1
|
|||
| InChIKey |
RJCWBNBKOKFWNY-IDPLTSGASA-N
|
|||
| CAS Number |
CAS 1474034-05-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Activator | [2] |
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216718. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin. Arch Dermatol Res. 2014 Jul;306(5):447-54. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.